.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AX16_Plerixafor.Plerixafor_1 .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L03A_Immunostimulants.L03AX16_Plerixafor.Plerixafor_1| name: | Plerixafor_1 |
| ATC code: | L03AX16_1 | route: | subcutaneous |
| n-compartments | 1 |
Plerixafor is a hematopoietic stem cell mobilizer that acts as a CXCR4 antagonist. It is used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma. Plerixafor is currently approved by regulatory agencies such as FDA and EMA for this indication.
Pharmacokinetic parameters in patients with varying degrees of renal impairment; after a single subcutaneous injection.
Cashen, A, et al., & DiPersio, J (2008). A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 14(11) 1253–1261. DOI:10.1016/j.bbmt.2008.08.011 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18940680
Lack, NA, et al., & Bridger, G (2005). A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100. Clinical pharmacology and therapeutics 77(5) 427–436. DOI:10.1016/j.clpt.2004.12.268 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15900288